Linking erectile dysfunction and coronary artery disease

International Journal of Impotence Research

Volumn 17, Issue SUPPL. S1, 2005, Pages

  Rodriguez, J J ^a   Al Dashti, R ^a   Schwarz, E R ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Atherosclerosis; Coronary artery disease; Endothelial dysfunction; Erectile dysfunction; Sexual function; Vascular disease

Indexed keywords

ADENOVIRUS VECTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GROWTH HORMONE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHOSPHODIESTERASE V INHIBITOR; REACTIVE OXYGEN METABOLITE; SILDENAFIL; SOMATOMEDIN; TESTOSTERONE; TISSUE PLASMINOGEN ACTIVATOR; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

CARDIOVASCULAR RISK; CELL BASED GENE THERAPY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORPUS CAVERNOSUM; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ERECTILE DYSFUNCTION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS GONAD SYSTEM; IMPOTENCE; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PLASMID; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; SMOOTH MUSCLE TONE; VASODILATATION; VIRAL GENE THERAPY;

CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; GENE THERAPY; HORMONES; HUMANS; HYPERTENSION; IMPOTENCE; MALE; OBESITY; SMOKING;

EID: 30044436690     PISSN: 09559930     EISSN: 14765489     Source Type: Journal    
DOI: 10.1038/sj.ijir.3901424     Document Type: Review

References (82)

1. Montorsi P et al. Common grounds for erectile dysfunction and coronary artery disease. Curr Opinion Urol 2004; 14: 361-365.
2. Gazzaruso C et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 2004; 110: 22-26.
3. Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1: 181-184.
4. Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: The Rancho Bernardo Study. J Am Coll Cardiol 2004; 43: 1405-1411.
5. Roose SP. Depression: links with ischemic heart disease and erectile dysfunction. J Clin Psychiatry. 2003; 64: 26-30.
6. Tan RS, Pu SJ. The interlinked depression, erectile dysfunction and coronary heart disease syndrome in older men: a triad often underdiagnosed. J Gend Specif Med 2003; 6: 31-36.
7. Solomon H, Man JW, Wierzbicki AS, Jackson G. Relation of erectile dysfunction to angiographic artery disease. Am J Cardiol 2003; 91: 230-231.
8. Greenstein A et al. Does severity of ischemic coronary disease correlate with erectile function? Int J Impot Res 1997; 9: 123-126.
9. Montorsi F et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003; 44: 360-364.
10. Shamloul R et al. Correlation between penile duplex findings and stress electrocardiography in men with erectile dysfunction. Int J Impot Res 2004; 16: 235-237.
11. Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Is erectile dysfunction predictive of peripheral vascular disease? Aging Male 2003; 6: 217-221.
12. Blumentals WA, Gomez-Caminero A, Joo S, Vannappagari V. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results of a retrospective cohort study. Int J Impot Res 2004; 16: 350-353.
13. Kirby M, Jackson G, Simonsen U. Endothelial dysfunction links erectile dysfunction to heart disease. Int J Clin Pract 2005; 59: 225-229.
14. Schachinger V, Zeiher AM. Prognostic implications of endothelial dysfunction: does it mean anything? Coronary Artery Dis 2001; 12: 435-443.
15. Brunner H et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246.
16. Andersson K, Stief C. Penile erection and cardiac risk: pathophysiologic and pharmacologic mechanisms. Am J Caridol 2000; 86: 23f-26f.
17. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999; 84: 11n-17n.
18. Jeremy JY et al. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cGMP and cAMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79: 958-963.
19. Yavuzgil O et al. Endothelial function in patients with vasculogenic erectile dysfunction. Int J Cardiol 2005; 103: 19-26.
20. Kaiser DR et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179-184.
21. Kharbanda RK, Deanfield JE. Functions of the healthy endothelium. Coran Artery Dis 2001; 12: 485-491.
22. Sagripanti A, Carpi A. Antithrombotic and prothrombotic activities of the vascular endothelium. Biomed Pharmacother 2000; 54: 107-111.
23. Panes J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. Br J Pharmacol 1999; 126: 537-550.
24. Mombouli J, Vanhoutte PM. Endothelial dysfunction: from physiology to therapy. J Mol Cell Cardiol 1999; 31: 61-74.
25. Fleming I, Busse R. Control and consequences of endothelial nitric oxide formation. Adv Pharmacol 1995; 34: 187-206.
26. Duffy SJ et al. Continuous release of vasodilator prostanoids contributes to regulation of resting forearm blood flow in humans. Am J Physiol 1998; 274: H1174-H1183.
27. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
28. Russell S, Nehra A. The physiology of erectile dysfunction. Herz 2003; 28: 277-283.
29. Saenz de Tejada I et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320: 1025-1030.
30. Escrig A et al. Changes in mating behavior, erectile function, and nitric oxide levels in penile corpora cavernosa in streptozotocin-diabetic rats. Biol Beprod 2002; 66: 185-189.
31. Vallance P, Chan N. Endothelial function and nitric oxide: clinical relevance. Heart 2001; 85: 342-350.
32. Leiper JM et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deaminases. Biochem J 1999; 343: 209-214.
33. Seftel AD et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition and possible effect through iNOS or eNOS. Urology 1997; 50: 1016-1026.
34. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001; 87: 402-407.
35. Jevtich MJ, Edson M, Jarman WD, Herrera HH. Vascular factor in erectile failure among diabetics. Urology 1982; 19: 163-168.
36. Francavilla S et al. Endothelin-1 in diabetic and non-diabetic men with erectile dysfunction. J Urol 1997; 158: 1770-1774.
37. Bell CR et al. The density and distribution of endothelin 1 and endothelin receptor subtypes in normal and diabetic rat corpus cavernosum. Br J Urol 1995; 76: 203-207.
38. Becker AJ et al. Systemic and cavernosal plasma levels of endothelin (1-21) during different penile conditions in healthy males and patients with erectile dysfunction. World J Urol 2001; 19: 371-376.
39. Takahashi K et al. Elevated plasma endothelin in patients with diabetes mellitus. Diabetalogia 1990; 33: 306-310.
40. Dogra G, Rich L, Stanton K, Watts GF. Endothelium-dependent and -independent vasodilation studies at normoglycaemia in type 1 diabetes mellitus with and without microalbuminuria. Diabetologia 2001; 44: 593-601.
41. Elliott TG et al. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependent diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci 1993; 85: 687-693.
42. Chowienczyk PJ et al. Oral treatment with an antioxidant (raxofelast) reduces oxidative stress and improves endothelial function in men with type 2 diabetes. Diabetologia 2000; 43: 974-977.
43. Jacobs M, Plane F, Bruckdorfer KR. Native and oxidized low-density-lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in the rabbit aorta. Br J Pharmacol 1990; 100: 21-26.
44. Head RJ. Hypernoradrenergic innervation: its relationship to functional and hyperplastic changes in the vasculature of spontaneously hypertensive rat. Blood Vessels 1989; 26: 1-20.
45. Bemelmans BL et al. Erectile dysfunction in diabetic men: the neurological factor revisited. J Urol 1994; 151: 884-889.
46. Blanco R et al. Dysfunctional penile cholinergic nerves in diabetic impotent men. J Urol 1999; 144: 278-280.
47. Melman A, Bressler RS, Henry DP, Macadoo VK. Ultrastructure of human penile erectile tissues in patients with abnormal norepinephrine content. Invest Urol 1981; 19: 46-48.
48. Panza JA, Quyyumi AA, Brush Jr JE, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323: 22-27.
49. Koga T et al. Age and hypertension promote endothelium-dependent contractions to acetylcholine in the aorta of the rat. Hypertension 1989; 14: 542-548.
50. Kung CF, Luscher TF. Different mechanisms of endothelial dysfunction with aging and hypertension in the rabbit aorta. Hypertension 1995; 25: 194-200.
51. Nakayama M et al. T-786-C mutation in the 5′flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99: 2864-2870.
52. Rossi GP et al. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003; 41: 938-945.
53. Taddei S et al. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension 1997; 29: 274-279.
54. Behr-Roussel D et al. Erectile dysfunction in spontaneously hypertensive rats: pathophysiological mechanisms. Am J Physiol Regul Integr Comp Physiol 2003; 284: R682-R688.
55. Calver A, Collier J, Moncada S, Vallance P. Effect of local intraarterial NG-monomethyl-L-arginine in patients with hypertension: nitric oxide dilator mechanism appears abnormal. J Hypertens 1992; 10: 1025-1031.
56. Folkow B. Structural factor' in primary and secondary hypertension. Hypertension 1990; 16: 89-101.
57. Toblli JE et al. Morphological changes in cavernous tissue in spontaneously hypertensive rats. Am J Hypertens 2000; 13: 686-692.
58. Quyyumi AA et al. Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. Circulation 1997; 95: 104-110.
59. Kuvin JT et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J 2002; 144: 165-172.
60. Lupattelli G et al. Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia. Am J Cardiol 2002; 90: 648-650.
61. Spieker LE et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105: 1399-1402.
62. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vas Biol 1999; 19: 972-978.
63. Ziccardi P et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-809.
64. Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96: 3042-3047.
65. Giugliano D et al. L-arginine for testing endothelium-dependent vascular functions in health and disease. Am J Physiol 1997; 273: E606-E612.
66. Perticone F et al. Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 2001; 50: 159-165.
67. Mather KJ et al. Endothelin contributes to basal vascular tone and endothelial dysfunction in human obesity and type 2 diabetes. Diabetes 2002; 51: 3517-3523.
68. Suwaidi JA et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-954.
69. Schachinger V, Zeiher AM. Quantitative assessment of coronary vasoreactivity in humans in vivo: importance of baseline vasomotor tone in atherosclerosis. Circulation 1995; 92: 2087-2094.
70. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
71. Hermann M, Berger P. Hormonal changes in aging men: a therapeutic indication? Exp Gerontol 2001; 36: 1075-1082.
72. Aversa A et al. Hormonal supplementation and erectile dysfunction. Euro Urol 2005; 47: 564.
73. Huang X, Li S, Hu L. Growth hormone deficiency and age-related erectile dysfunction. Zhonghus Nan Ke Xue 2004; 10: 867-869.
74. Li S, Hu L, Zhao J. Effect of growth hormone on erectile function and number of nNOS-containing verve fibers in internal iliac arterial ligation rats. Zhonghua Nan Ke Xue 2004; 10: 103-106.
75. Becker AJ et al. Growth hormone, somatomedins and men's health. Aging Male 2002; 5: 258-262.
76. Bivalacqua TJ et al. Gene therapy techniques for the delivery of endothelial nitric oxide synthase to the corpa cavernosa for erectile dysfunction. Methods Mol Biol 2004; 279: 173-185.
77. Bivalacqua TJ et al. Effect of combination endothelial nitric oxide synthase gene therapy and sildenafil on erectile function in diabetic rats. Int J Impot Res 2004; 16: 21-29.
78. Bivalacqua TJ et al. Gene transfer of endothelial nitric oxide synthase partially restores nitric oxide synthesis and erectile function in streptozotocin diabetic rats. J Urol 2003; 169: 1911-1917.
79. Akinba AG, Burnett AL. Endothelial nitric oxide synthase protein expression, localization, and activity in the penis of the alloxan-induced diabetic rat. Mol Urol 2001; 5: 189-197.
80. Champion HC et al. Gene transfer of endothelial nitric oxide synthase to the penis augments erectile responses in the aged rat. Pharmacology 1999; 96: 11648-11652.
81. Tirney S et al. Nitric oxide synthase gene therapy for erectile dysfunction: comparison of plasmid, adenovirus, and adeno virus-transduced myoblast vectors. Mol Urol 2001; 5: 37-43.
82. Archer SL. Potassium channels and erectile dysfunction. Vascul Pharmacol 2002; 38: 61-71.